I’m happy to share those first results of our Phase II trial evaluating three drugs: atezolizumab, an anti-PD-L1 antibody, obinutuzumab, an anti-CD20 antibody, and venetoclax, a small-molecule inhibiting BCL2. So, those three drugs were given to relapsed and refractory follicular lymphoma and marginal zone lymphomas.
And we are sharing during EHA the first results with no safety signal brought by the combination of the three drugs...
I’m happy to share those first results of our Phase II trial evaluating three drugs: atezolizumab, an anti-PD-L1 antibody, obinutuzumab, an anti-CD20 antibody, and venetoclax, a small-molecule inhibiting BCL2. So, those three drugs were given to relapsed and refractory follicular lymphoma and marginal zone lymphomas.
And we are sharing during EHA the first results with no safety signal brought by the combination of the three drugs. So, that’s really a good news. And we have the toxicity of the single drugs with some cytopenias, and some autoimmune adverse events brought by atezolizumab probably, but everything was manageable, and, for example, we had only one neutropenia on our cohorts.
So, we had 58 follicular lymphoma with an overall response rate of 53%, and we have also 20 marginal zone lymphomas with an overall response rate of 66.7%. So, this is some primary results, but this is really promising without chemo and with the responses that are durable so far with a median follow-up of 14 months.